Literature DB >> 26925626

Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications.

Ibrahim O Alanazi1, Zahid Khan.   

Abstract

Epidermal growth factor receptors (EGFRs/HERs) and downstream signaling pathways have been implicated in the pathogenesis of several malignancies including breast cancer and its resistance to treatment with chemotherapeutic drugs. Consequently, several monoclonal antibodies as well as small molecule inhibitors targeting these pathways have emerged as therapeutic tools in the recent past. However, studies have shown that utilizing these molecules in combination with chemotherapy has yielded only limited success. This review describes the current understanding of EGFRs/HERs and associated signaling pathways in relation to development of breast cancer and responses to various cancer treatments in the hope of pointing to improved prevention, diagnosis and treatment. Also, we review the role of breast cancer stem cells (BCSCs) in disease and the potential to target these cells.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26925626     DOI: 10.7314/apjcp.2016.17.2.445

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  13 in total

1.  Imbalance of the reciprocally inhibitory loop between the ubiquitin-specific protease USP43 and EGFR/PI3K/AKT drives breast carcinogenesis.

Authors:  Lin He; Xinhua Liu; Jianguo Yang; Wanjin Li; Shumeng Liu; Xujun Liu; Ziran Yang; Jie Ren; Yue Wang; Lin Shan; Chengjian Guan; Fei Pei; Liandi Lei; Yu Zhang; Xia Yi; Xiaohan Yang; Jing Liang; Rong Liu; Luyang Sun; Yongfeng Shang
Journal:  Cell Res       Date:  2018-08-22       Impact factor: 25.617

Review 2.  Fucoxanthin Is a Potential Therapeutic Agent for the Treatment of Breast Cancer.

Authors:  Tsz-Ying Lau; Hiu-Yee Kwan
Journal:  Mar Drugs       Date:  2022-05-30       Impact factor: 6.085

Review 3.  Risk Factors and Preventions of Breast Cancer.

Authors:  Yi-Sheng Sun; Zhao Zhao; Zhang-Nv Yang; Fang Xu; Hang-Jing Lu; Zhi-Yong Zhu; Wen Shi; Jianmin Jiang; Ping-Ping Yao; Han-Ping Zhu
Journal:  Int J Biol Sci       Date:  2017-11-01       Impact factor: 6.580

4.  ZNF516 suppresses EGFR by targeting the CtBP/LSD1/CoREST complex to chromatin.

Authors:  Lifang Li; Xinhua Liu; Lin He; Jianguo Yang; Fei Pei; Wanjin Li; Shumeng Liu; Zhe Chen; Guojia Xie; Bosen Xu; Xia Ting; Zihan Zhang; Tong Jin; Xujun Liu; Wenting Zhang; Shuai Yuan; Ziran Yang; Chongyang Wu; Yu Zhang; Xiaohan Yang; Xia Yi; Jing Liang; Yongfeng Shang; Luyang Sun
Journal:  Nat Commun       Date:  2017-09-25       Impact factor: 14.919

5.  SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR.

Authors:  Lina Zhao; Ting Qiu; Dewei Jiang; Haibo Xu; Li Zou; Qin Yang; Ceshi Chen; Baowei Jiao
Journal:  Adv Sci (Weinh)       Date:  2020-06-08       Impact factor: 16.806

Review 6.  Mechanistic Pathways of Malignancy in Breast Cancer Stem Cells.

Authors:  Saghar Yousefnia; Farzad Seyed Forootan; Shiva Seyed Forootan; Mohammad Hossein Nasr Esfahani; Ali Osmay Gure; Kamran Ghaedi
Journal:  Front Oncol       Date:  2020-04-30       Impact factor: 6.244

Review 7.  Immunomodulatory Effects of Flavonoids: Possible Induction of T CD4+ Regulatory Cells Through Suppression of mTOR Pathway Signaling Activity.

Authors:  Aysooda Hosseinzade; Omid Sadeghi; Akram Naghdipour Biregani; Sepideh Soukhtehzari; Gabriel S Brandt; Ahmad Esmaillzadeh
Journal:  Front Immunol       Date:  2019-01-31       Impact factor: 7.561

Review 8.  Signaling pathways governing breast cancer stem cells behavior.

Authors:  Kai Song; Maryam Farzaneh
Journal:  Stem Cell Res Ther       Date:  2021-04-16       Impact factor: 6.832

9.  Establishment and characterization of novel highly aggressive HER2‑positive and triple‑negative breast cancer cell lines.

Authors:  Suyanee Thongchot; Pranisa Jamjuntra; Jaturawitt Prasopsiri; Peti Thuwajit; Nunghathai Sawasdee; Naravat Poungvarin; Malee Warnnissorn; Doonyapat Sa-Nguanraksa; Pornchai O-Charoenrat; Pa-Thai Yenchitsomanus; Chanitra Thuwajit
Journal:  Oncol Rep       Date:  2021-10-15       Impact factor: 3.906

10.  Guizhi Fuling Decoction inhibiting the PI3K and MAPK pathways in breast cancer cells revealed by HTS2 technology and systems pharmacology.

Authors:  Yifei Dai; Weijie Qiang; Xiankuo Yu; Siwei Cai; Kequan Lin; Lan Xie; Xun Lan; Dong Wang
Journal:  Comput Struct Biotechnol J       Date:  2020-05-18       Impact factor: 7.271

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.